ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
ACADIA PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$19.80+0.68 (+3.56%)
Close on Oct 19, 2026
- Market cap
- $3.42B
- P/E (TTM)
- 9.0
- Dividend yield
- –
Share price
−$1.09 (−5.22%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ACADIA PHARMACEUTICALS INC grew revenue 11.8% to $1.14B over the twelve months to Jun 30, 2026. Operating income fell 63.5% to $86.37M, moving the operating margin from 23.2% to 7.6%. Free cash flow was $145.63M, down 22.2% from a year earlier.
Revenue
$1.14B
+11.8% vs. a year earlier
Operating income
$86.37M
-63.5% vs. a year earlier
Free cash flow
$145.63M
-22.2% vs. a year earlier
EPS, diluted
$2.21
+66.2% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.42B
- P/E ratio
- 9.0
- Price to sales
- 3.01
- Price to book
- 2.62
- Dividend yield
- –
- Free cash flow yield
- 4.25%
Fundamentals
- Revenue
- $1.14B
- Net income
- $380.48M
- EPS, diluted
- $2.21
- Free cash flow
- $145.63M
- Book value per share
- $7.56
- Diluted shares
- 173M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$1.14B+11.8% YoY
Gross profit
$1.04B+10.7% YoY
Operating income
$86.37M-63.5% YoY
Net income
$380.48M+71.3% YoY
EPS, diluted
$2.21+66.2% YoY
Free cash flow
$145.63M-22.2% YoY
Reported periodTrailing twelve months